Breaking News

ShangPharma Restructures CRO and CMO Ops

Will consolidate all contract services under Shanghai ChemPartner

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ShangPharma has unveiled plans for a corporate restructuring. The company will be consolidating the contract research organizations (CRO) and contract manufacturing organizations (CMO) under Shanghai ChemPartner. These entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner Chengdu, ChemPartner US, ChemPartner Europe, China Gateway Pharmaceutical Development, China Gateway Biologics, ChemExplorer Hong Kong, and ChemExplorer Shanghai. The company says its intention is to enter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters